Brief: Coya Therapeutics Inc Provides Business Update And Reports Q1 2023 Unaudited Financial Results
10/05/2023 13:55
May 10 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND
REPORTS Q1
2023 UNAUDITED FINANCIAL RESULTS
* SAYS AS OF MARCH 31, 2023, COYA HAD CASH AND CASH
EQUIVALENTS OF
$16.3 MILLION
* QTRLY NET LOSS PER SHARE OF COMMON STOCK, BASIC AND
DILUTED
$0.28
Source text for Eikon: ID:nBwbGJxX1a
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)